PUBLISHER: The Business Research Company | PRODUCT CODE: 1889616
PUBLISHER: The Business Research Company | PRODUCT CODE: 1889616
Viscosupplementation treatment for arthritis is a medical therapy in which a gel-like substance, usually hyaluronic acid, is injected into a joint to enhance lubrication and reduce pain. This treatment helps restore the joint's natural cushioning and shock-absorbing abilities, particularly in osteoarthritis. It is often recommended when conventional treatments-such as pain relievers or physical therapy-are not sufficient to manage joint discomfort and stiffness.
The main product types of viscosupplementation treatment for arthritis include single injection, three injections, and five injections. Single-injection viscosupplementation refers to administering one dose of hyaluronic acid or a similar lubricant into the joint to relieve pain, improve mobility, and restore joint cushioning. These treatments are used for conditions such as knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, and others, and are utilized by end users including hospitals, ambulatory surgical centers, orthopedic clinics, and other healthcare facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The viscosupplementation treatment for arthritis market research report is one of a series of new reports from The Business Research Company that provides viscosupplementation treatment for arthritis market statistics, including viscosupplementation treatment for arthritis industry global market size, regional shares, competitors with a viscosupplementation treatment for arthritis market share, detailed viscosupplementation treatment for arthritis market segments, market trends and opportunities, and any further data you may need to thrive in the viscosupplementation treatment for arthritis industry. This viscosupplementation treatment for arthritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The viscosupplementation treatment for arthritis market size has grown strongly in recent years. It will grow from $3.87 billion in 2024 to $4.18 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. Growth during the historic period can be attributed to the rising prevalence of osteoarthritis among aging populations, increasing awareness of non-surgical treatment options, growing adoption of minimally invasive therapies, the expanding number of orthopedic clinics offering injections, and greater patient preference for pain relief without systemic side effects.
The viscosupplementation treatment for arthritis market size is expected to see strong growth in the next few years. It will grow to $5.57 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. Growth in the forecast period can be attributed to a growing elderly population, increasing awareness of early intervention in arthritis care, rising demand for outpatient and home-based treatments, wider adoption of advanced hyaluronic acid formulations, and an increasing number of clinical trials. Major trends expected in the forecast period include the development of combination therapies, integration with telemedicine platforms, advancements in sustained-release formulations, incorporation of regenerative medicine approaches, and the emergence of cost-effective biosimilar products.
The increasing prevalence of osteoarthritis is expected to drive the growth of the viscosupplementation treatment market for arthritis. Osteoarthritis is a chronic joint condition marked by the gradual breakdown of cartilage, leading to pain, stiffness, and reduced mobility. The rise in osteoarthritis cases is largely attributed to an aging population, as the natural wear and tear of joints makes older adults more prone to the condition. Viscosupplementation treatments help manage osteoarthritis by restoring joint lubrication, easing pain, and improving mobility. For example, in February 2025, Springer Nature Group, a UK-based academic publisher, estimated that there were 12.94 million cases of knee osteoarthritis in men and 18.80 million in women. By 2046, these figures are expected to rise to 18.45 million in men and 25.60 million in women. As such, the growing prevalence of osteoarthritis is fueling the expansion of the viscosupplementation treatment market.
The increasing healthcare expenditure is expected to drive market growth due to the rising demand for advanced medical services and technological innovations. Healthcare spending is growing because of the higher prevalence of chronic diseases, which require ongoing medical care and treatments. This spending supports the viscosupplementation treatment market by improving access to advanced therapies, funding research and development, and making treatments more affordable for patients managing osteoarthritis. For instance, in June 2025, the Centers for Medicare & Medicaid Services (CMS) reported that in 2023, national health expenditures (NHE) increased by 7.5% to reach $4.9 trillion, averaging $14,570 per person and representing 17.6% of the U.S. GDP. Medicare spending rose by 8.1% to $1,029.8 billion, accounting for 21% of the total NHE. As a result, rising healthcare expenditure is contributing to the growth of the viscosupplementation treatment market.
Major players in the viscosupplementation treatment market are focused on developing innovative solutions, such as advanced hyaluronic acid formulations, to improve joint lubrication, reduce pain, and enhance mobility for musculoskeletal conditions. These enhanced hyaluronic acid formulations are designed with an optimized molecular structure and viscosity to provide longer-lasting lubrication and more effective pain relief in arthritis treatments. For example, in February 2024, IBSA Group, a Switzerland-based pharmaceutical company, launched the SINOVIAL range, a next-generation viscosupplementation treatment. This range uses NAHYCO technology, which combines high and low molecular weight hyaluronic acid to offer effective joint lubrication and extended pain relief. These treatments mimic the functions of natural synovial fluid, improving joint cushioning and shock absorption. The injectable formulations provide optimal viscosity and excellent patient tolerance, enhancing comfort, mobility, and osteoarthritis management.
Major companies operating in the viscosupplementation treatment for arthritis market are Johnson And Johnson, Sanofi S.A., LG Chem Ltd., Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zimmer Biomet Holdings Inc., Singapore Health Services Pte Ltd., IBSA Group, Bioventus LLC, Fidia Farmaceutici S.p.A., Ferring Pharmaceuticals A/S, Anika Therapeutics Inc., TRB Chemedica International S.A., Laboratoires VIVACY, Seikagaku Corporation, Regen Lab SA, OrthogenRx Inc., Wellchem Pharmaceuticals Pte Ltd., Shanghai Haohai Biological Technology Co. Ltd., Miravo Healthcare.
North America was the largest region in the viscosupplementation treatment for arthritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in viscosupplementation treatment for arthritis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the viscosupplementation treatment for arthritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The viscosupplementation treatment for arthritis market consists of revenues earned by entities by providing services such as joint assessment and imaging services, physical therapy support, post-injection monitoring and follow-up, arthroscopic guidance services, and customized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The viscosupplementation treatment market also includes sales of hyaluronic acid injections, cross-linked hyaluronic acid formulations, multi-dose hyaluronic acid syringes, combination therapies, and biologically derived viscosupplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Viscosupplementation Treatment For Arthritis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on viscosupplementation treatment for arthritis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for viscosupplementation treatment for arthritis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The viscosupplementation treatment for arthritis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.